Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis

Transplantation Proceedings

Volumn 48, Issue 5, 2016, Pages 1687-1691

  Grat M ^a   Wronka, K M ^a   Krasnodebski M ^a   Masior, L ^a   Lewandowski, Z ^a   Kosinska I ^a   Grat K ^a   Stypulkowski J ^a   Rejowski, S ^a   Wasilewicz, M ^a   Galecka M ^b   Szachta, P ^b   Krawczyk, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Institute of Microecology   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ALCOHOL LIVER DISEASE; ARTICLE; BACTERIAL COUNT; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE ASSOCIATION; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INTESTINE FLORA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEX; TUMOR INVASION; COMPLICATION; DISEASE COURSE; LIVER TUMOR; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; DISEASE PROGRESSION; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84991271558     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2016.01.077     Document Type: Article

References (31)

1. [1] Brenner, D.A., Paik, Y.H., Schnabl, B., Role of gut microbiota in liver disease. J Clin Gastroenterol 49 (2015), S25–S27.
2. [2] Minemura, M., Shimizu, Y., Gut microbiota and liver diseases. World J Gastroenterol 21 (2015), 1691–1702.
3. [3] Giannelli, V., Di Gregorio, V., Iebba, V., Giusto, M., Schippa, S., Merli, M., et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 20 (2014), 16795–16810.
4. [4] Chassaing, B., Etienne-Mesmin, L., Gewirtz, A.T., Microbiota-liver axis in hepatic disease. Hepatology 59 (2014), 328–339.
5. [5] Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513 (2014), 59–64.
6. [6] Bajaj, J.S., Betrapally, N.S., Hylemon, P.B., Heuman, D.M., Daita, K., White, M.B., et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology 62 (2015), 1260–1271.
7. [7] Grąt, M., Hołówko, W., Gałecka, M., Grąt, K., Szachtaz, P., Lewandowsk, Z., et al. Gut microbiota in cirrhotic liver transplant candidates. Hepatogastroenterology 61 (2014), 1661–1667.
8. [8] Grąt, M., Hołówko, W., Wronka, K.M., Grąt, K., Lewandowski, Z., Kosińska, I., et al. The relevance of intestinal dysbiosis in liver transplant candidates. Transpl Infect Dis 17 (2015), 174–184.
9. [9] McGlynn, K.A., Petrick, J.L., London, W.T., Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19 (2015), 223–238.
10. [10] Hong, T.P., Gow, P., Fink, M., Dev, A., Roberts, S., Nicoll, A., et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology 63 (2016), 1205–1212.
11. [11] Grąt, M., Hołówko, W., Grzegorczyk, K., Skalski, M., Krawczyk, M., Long-term results of liver resection in the treatment of patients with hepatocellular carcinoma. Pol Przegl Chir 83 (2011), 319–324.
12. [12] Grąt, M., Kornasiewicz, O., Lewandowski, Z., Hołówko, W., Grąt, K., Kobryń, K., et al. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 38 (2014), 2698–2707.
13. [13] Yu, J., Hosmer, A., Parks, T., Sonnenday, C.J., Sharma, P., Predictors of early hospitalization after deceased donor liver transplantation. Dig Dis Sci 60 (2015), 3242–3247.
14. [14] Wong, R.J., Cheung, R., Perumpail, R.B., Holt, E.W., Ahmed, A., Diabetes mellitus, and not obesity, is associated with lower survival following liver transplantation. Dig Dis Sci 60 (2015), 1036–1044.
15. [15] Grąt, M., Wronka, K.M., Patkowski, W., Stypułkowski, J., Grąt, K., Krasnodębski, M., et al. Effects of donor age and cold ischemia on liver transplantation outcomes according to the severity of recipient status. Dig Dis Sci 61 (2016), 626–635.
16. [16] Sun, B., Karin, M., Inflammation and liver tumorigenesis. Front Med 7 (2013), 242–254.
17. [17] Ding, J., Wang, H., Multiple interactive factors in hepatocarcinogenesis. Cancer Lett 346 (2014), 17–23.
18. [18] Zhang, H.L., Yu, L.X., Yang, W., Tang, L., Lin, Y., Wu, H., et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 57 (2012), 803–812.
19. [19] Yoshimoto, S., Loo, T.M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
20. [20] Fox, J.G., Feng, Y., Theve, E.J., Raczynski, A.R., Fiala, J.L., Doernte, A.L., et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59 (2010), 88–97.
21. [21] Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
22. [22] Pellicano, R., Mazzaferro, V., Grigioni, W.F., Cutufia, M.A., Fagoonee, S., Silengo, L., et al. Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma. World J Gastroenterol 10 (2004), 598–601.
23. [23] Esmat, G., El-Bendary, M., Zakarya, S., Ela, M.A., Zalata, K., Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J Viral Hepat 19 (2012), 473–479.
24. [24] Dore, M.P., Realdi, G., Mura, D., Graham, D.Y., Sepulveda, A.R., Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Dig Dis Sci 47 (2002), 1638–1643.
25. [25] Dhiman, R.K., Rana, B., Agrawal, S., Garg, A., Chopra, M., Thumburu, K.K., et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147 (2014), 1327–1337.
26. [26] Mittal, V.V., Sharma, B.C., Sharma, P., Sarin, S.K., A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 23 (2011), 725–732.
27. [27] Bajaj, J.S., Heuman, D.M., Hylemon, P.B., Sanyal, A.J., Puri, P., Sterling, R.K., et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 39 (2014), 1113–1125.
28. [28] Raisch, J., Buc, E., Bonnet, M., Sauvanet, P., Vazeille, E., de Vallée, A., et al. Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation. World J Gastroenterol 20 (2014), 6560–6572.
29. [29] Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One, 8, 2013, e56964.
30. [30] Bonnet, M., Buc, E., Sauvanet, P., Darcha, C., Dubois, D., Pereira, B., et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 20 (2014), 859–867.
31. [31] Chochi, K., Ichikura, T., Kinoshita, M., Majima, T., Shinomiya, N., Tsujimoto, H., et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res 14 (2008), 2909–2917.